Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) EBIT Margin (2016 - 2022)

Summit Therapeutics filings provide 7 years of EBIT Margin readings, the most recent being 7700.0% for Q3 2022.

  • Quarterly EBIT Margin fell 621138.0% to 7700.0% in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 268266.82% through Jun 2023, down 26433611.0% year-over-year, with the annual reading at 10225.39% for FY2022, 546110.0% down from the prior year.
  • EBIT Margin hit 7700.0% in Q3 2022 for Summit Therapeutics, down from 5400.85% in the prior quarter.
  • Across five years, EBIT Margin topped out at 64.52% in Q3 2018 and bottomed at 41631.58% in Q2 2021.
  • Average EBIT Margin over 5 years is 6559.06%, with a median of 5144.47% recorded in 2019.
  • The largest annual shift saw EBIT Margin plummeted -3259864bps in 2021 before it skyrocketed 3623073bps in 2022.
  • Summit Therapeutics' EBIT Margin stood at 1385.05% in 2018, then tumbled by -348bps to 6205.65% in 2019, then decreased by -1bps to 6246.49% in 2020, then plummeted by -66bps to 10377.29% in 2021, then increased by 26bps to 7700.0% in 2022.
  • Per Business Quant, the three most recent readings for SMMT's EBIT Margin are 7700.0% (Q3 2022), 5400.85% (Q2 2022), and 8863.2% (Q1 2022).